Home How RBC Capital Called A 50% Gain In This Biotech Stock
 

Keywords :   


How RBC Capital Called A 50% Gain In This Biotech Stock

2015-04-02 14:18:31| Biotech - Topix.net

Shares of Dyax Corp. closed up more than 53 percent on Wednesday after the company announced positive results from an early-stage test of its drug DX-2930 on treatment of Hereditary Angioedema . Benzinga had the chance to speak with Dyax's Executive Vice President of R&D, Dr. Burt Adelman, about what the results mean for the company.

Tags: this called stock capital

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
06.11Stocks and dollar rise as US election result in focus
06.11Hurricane Rafael Update Statement
06.11Summary for Hurricane Rafael (AT3/AL182024)
06.11Warning millions will struggle to pay water bill rises
06.11Atlantic Tropical Weather Outlook
06.11Tropical Storm Rafael Graphics
06.11Tropical Storm Rafael Public Advisory Number 9A
06.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »